Serial #79278845
LIVE

Serial Number

79278845

Owner

Jiangsu Ascentage Pharma Inc.

Attorney

Kathryn E. Smith

Filing Date

Dec 13, 2019

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79278845 Trademark

Serial Number: 79278845 • Registration: 6253552

Serial #79278845 is a trademark filed by Jiangsu Ascentage Pharma Inc. on December 13, 2019. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Jiangsu Ascentage Pharma Inc. (6 trademarks)

101 Room Of First Floor, Qb3 Buiding,

Entity Type: 99

ASCENTAGE PHARMA (SUZHOU) CO., LTD. (23 trademarks)

68 XINQING ROAD
SUZHOU 215000 , CN

Entity Type: 03

Trademark Details

Filing Date

December 13, 2019

Registration Date

January 26, 2021

Published for Opposition

November 10, 2020

Goods & Services

Biochemical medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antiseptics; collyrium; suppositories; medicinal oil solutions for medical purposes; hemostatic paste for medical purposes; bone paste for medical purpose; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; candy, medicated; candy for medical purposes; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic preparations adapted for medical use; mineral food supplements; nutritional supplements; drugs for human purposes, namely, medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bacterial poisons; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations in the form of tablets, lozenges, chews, gels, fast dispersing dosage forms, films, ovules, sprays, buccal and mucoadhesive patches for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bulk drugs, namely, active pharmaceutical ingredients in the nature of drug delivery agents in the form of tablets, lozenges, chews, gels, fast dispersing dosage forms, films, ovules, sprays, buccal and mucoadhesive patches that facilitate the delivery of pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compounds, kinase inhibitors and senolytic drugs; prescription drugs for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biological preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease medical purposes; chemical preparations for pharmaceutical or medical purposes, namely, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations in the form of injectables for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations in the form of tablet for the treatment of cancer, tumors, blood-related diseases, infectious diseases, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical preparations for medical purposes, namely, active pharmaceutical ingredients in the nature of drug delivery agents in the form of powders, liquids, and capsules that provide controlled release of active ingredients for a wide variety of pharmaceuticals; chemical preparations for medical purposes, namely, active pharmaceutical ingredients in the nature of drug delivery agents in the form of tablets that facilitate the delivery of pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations in the nature of transdermal patches for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; medicines for dental purposes; chemical preparations for medical purposes for treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antibiotics; tablets for medical purposes in the nature of vitamin tablets

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Apr 23, 2026 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jan 26, 2026 REM3
CHANGE OF OWNER RECEIVED FROM IB
Nov 7, 2025 CHLD
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 21, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Aug 21, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 21, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 21, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 21, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 21, 2025 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 26, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 26, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 26, 2024 REAP
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Dec 26, 2023 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Dec 26, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Dec 26, 2023 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Dec 26, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Dec 26, 2023 REAP
CORRECTION UNDER SECTION 7 - PROCESSED
Nov 23, 2021 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Nov 20, 2021 APRE
TEAS SECTION 7 REQUEST RECEIVED
Jun 24, 2021 ES7R
FINAL DECISION TRANSACTION PROCESSED BY IB
May 23, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 30, 2021 FICS
FINAL DISPOSITION PROCESSED
Apr 30, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 26, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Jan 26, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 10, 2020 NPUB
PUBLISHED FOR OPPOSITION
Nov 10, 2020 PUBO
NOTIFICATION PROCESSED BY IB
Nov 8, 2020 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 21, 2020 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 21, 2020 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 21, 2020 NONP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 6, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 6, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 6, 2020 REAP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 5, 2020 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 5, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 5, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 5, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 5, 2020 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 16, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 16, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 16, 2020 TROA
REFUSAL PROCESSED BY IB
Apr 24, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 7, 2020 RFCS
REFUSAL PROCESSED BY MPU
Apr 7, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 22, 2020 RFCR
NON-FINAL ACTION WRITTEN
Mar 21, 2020 CNRT
ASSIGNED TO EXAMINER
Mar 13, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 25, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 19, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 13, 2020 REPR